However, medical history, concurrent medications, and baseline weight loss goals should guide your provider's assessment of whether this dose is appropriate for your situation
Reports of changes in facial appearance after GLP-1 drug usesuch as sunken eyes, wrinkles, facial aging and sagging skinhave been dubbed 'Ozempic face'
Eli Lillys oral small-molecule GLP-1, orforglipron (Foundayo), was FDA-approved April 1, 2026, but it is not tirzepatide and produces less weight loss (11.2% at 72 weeks)
The key is understanding what each treatment is designed to do and setting realistic expectations
Glutathione l mt cht chng oxy ha quan trng, c sn xut t nhin trong c th